Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth N Dow

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2019
Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicitiesCatherine E Renna, Elizabeth N Dow, Jason J Bergsbaken, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 7, 2020
PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and costEmily R Hennes, Elizabeth N Dow-Hillgartner, Jason J Bergsbaken, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 21, 2020
Hypertension and QT interval prolongation associated with targeted systemic cancer therapiesOlivia G Fahey, Jennifer K Piccolo, Jason J Bergsbaken, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 16, 2020
Current state assessment survey of challenges of pharmacogenomics within oncology pharmacy practiceDaniel J Przybylski, Elizabeth N Dow-Hillgartner, Michael P Reed, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|April 13, 2019
Expansion of pharmacist clinical services to optimize the management of immune checkpoint inhibitor toxicitiesCatherine E Renna, Elizabeth N Dow, Jason J Bergsbaken, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 7, 2020
PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and costEmily R Hennes, Elizabeth N Dow-Hillgartner, Jason J Bergsbaken, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 21, 2020
Hypertension and QT interval prolongation associated with targeted systemic cancer therapiesOlivia G Fahey, Jennifer K Piccolo, Jason J Bergsbaken, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|January 16, 2020
Current state assessment survey of challenges of pharmacogenomics within oncology pharmacy practiceDaniel J Przybylski, Elizabeth N Dow-Hillgartner, Michael P Reed, et al.
Pageof 1